2020-004194-51: A clinical trial evaluating the efficacy and safety of the drugs - cyclosporine and methotrexate in children and adolescents with moderate to severe atopic dermatitis. Badanie kliniczne oceniające skuteczność i bezpieczeństwo stosowania leków - cyklosporyny i metotreksatu u dzieci i młodzieży z atopowym zapaleniem skóry o nasileniu umiarkowanym do ciężkiego. |
|
|
| Not yet recruiting | 3 | 317 | Europe | Cyclosporin, Methotrexate, Mometasone furoate, Tacrolimus, Oral solution, Ointment | Medical University of Lodz, Medical Research Agency | Atopic dermatitis Atopowe Zapalenie Skóry, Atopic dermatitis Atopowe Zapalenie Skóry, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
BREEZE-AD4, NCT03428100 / 2017-004574-34: A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable |
|
|
| Completed | 3 | 463 | Europe, Japan, RoW | Baricitinib, LY3009104, Placebo, Topical corticosteroid | Eli Lilly and Company, Incyte Corporation | Atopic Dermatitis | 11/19 | 04/23 | | |
NCT05149313 / 2021-002967-23: A Study of Lebrikizumab in Combination With Topical Corticosteroids in Participants Having Atopic Dermatitis (AD) That Are Not Adequately Controlled or Non-eligible for Cyclosporine |
|
|
| Completed | 3 | 331 | Europe | Lebrikizumab, Lebrikizumab-matching Placebo | Almirall, S.A. | Dermatitis, Atopic, Eczema | 01/23 | 05/24 | | |